Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients

Sarah Walter, Amos Baruch, Jin Dong, James E. Tomlinson, Shawn T. Alexander, Julie Janes, Tom Hunter, Qun Yin, Derek Maclean, Gregory Bell, Dirk B. Mendel, Randolph M. Johnson and Felix Karim
Journal of Pharmacology and Experimental Therapeutics August 2013, 346 (2) 229-240; DOI: https://doi.org/10.1124/jpet.113.204834
Sarah Walter
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amos Baruch
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin Dong
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James E. Tomlinson
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shawn T. Alexander
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Janes
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Hunter
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qun Yin
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek Maclean
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Bell
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk B. Mendel
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randolph M. Johnson
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felix Karim
Amgen, Inc., South San Francisco, California (S.W., A.B., J.D., J.E.T., S.T.A., J.J., T.H., Q.Y., D.B.M., G.B., D.M., R.M.J., F.K.); and Department of Medicine, University of California, San Francisco, California (G.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A novel peptide, AMG 416 (formerly KAI-4169, and with a United States Adopted Name: velcalcetide), has been identified that acts as an agonist of the calcium-sensing receptor (CaSR). This article summarizes the in vitro and in vivo characterization of AMG 416 activity and the potential clinical utility of this novel compound. AMG 416 activates the human CaSR in vitro, acting by a mechanism distinct from that of cinacalcet, the only approved calcimimetic, since it can activate the CaSR both in the presence or the absence of physiologic levels of extracellular calcium. Administration of AMG 416 in vivo into either normal or renally compromised rats results in dose-dependent reductions in parathyroid hormone (PTH) levels and corresponding decreases in serum calcium, regardless of the baseline level of PTH. Treatment of 5/6 nephrectomized rats with AMG 416 resulted in dramatic improvements in their metabolic profile, including lower PTH and serum creatinine levels, reduced amounts of vascular calcification, attenuated parathyroid hyperplasia, and greater expression of the parathyroid gland regulators CaSR, vitamin D receptor, and FGF23 receptor compared with vehicle-treated animals. No drug accumulation was observed under this dosing regimen, and the terminal half-life of AMG 416 was estimated to be 2–4.5 hours. As a long-acting CaSR agonist, AMG 416 is an innovative new therapy for the treatment of hemodialysis patients with secondary hyperparathyroidism.

Footnotes

    • Received March 15, 2013.
    • Accepted May 14, 2013.
  • Portions of this work were previously presented at the following meeting: Walter S, Dong J, Alexander S, Hunter T, Yin K, Maclean D, Tomlinson J, Karim F, and Johnson R (2012) KAI-4169, a novel peptide agonist of the CaSR, attenuates PTH and soft tissue calcification and restores parathyroid gland VDR levels in uremic rats. ERA-EDTA Congress; 2012 May 24–27; Paris, France.

  • S.W. and A.B. contributed equally to this work.

  • dx.doi.org/10.1124/jpet.113.204834.

  • Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 346 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 346, Issue 2
1 Aug 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

AMG 416 (Velcalcetide) Activates the Calcium Sensing Receptor

Sarah Walter, Amos Baruch, Jin Dong, James E. Tomlinson, Shawn T. Alexander, Julie Janes, Tom Hunter, Qun Yin, Derek Maclean, Gregory Bell, Dirk B. Mendel, Randolph M. Johnson and Felix Karim
Journal of Pharmacology and Experimental Therapeutics August 1, 2013, 346 (2) 229-240; DOI: https://doi.org/10.1124/jpet.113.204834

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

AMG 416 (Velcalcetide) Activates the Calcium Sensing Receptor

Sarah Walter, Amos Baruch, Jin Dong, James E. Tomlinson, Shawn T. Alexander, Julie Janes, Tom Hunter, Qun Yin, Derek Maclean, Gregory Bell, Dirk B. Mendel, Randolph M. Johnson and Felix Karim
Journal of Pharmacology and Experimental Therapeutics August 1, 2013, 346 (2) 229-240; DOI: https://doi.org/10.1124/jpet.113.204834
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glucose transport modulators and mouse behavioral testing
  • Translational PK/PD Modeling of M3258
  • Kidney protective effects of BI 685509
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics